48. 原発性抗リン脂質抗体症候群 Disease details / Clinical trials / Drug dev / DR info /
臨床試験数 : 5 / 薬物数 : 6 - (DrugBank : 4) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 7
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
EPA and DHA supplementation
University of Sao Paulo
2014 - NCT01956188 Brazil;
Hydroxychloroquine
National and Kapodistrian University of Athens
2013 - NCT04153201 Greece;
University Hospital, Angers
2018 Phase 3 NCT03540810 France;
Telitacicept
Peking Union Medical College Hospital
2021 Phase 2 NCT05078710 China;
University of Sao Paulo
2014 - NCT01956188 Brazil;
Hydroxychloroquine
National and Kapodistrian University of Athens
2013 - NCT04153201 Greece;
University Hospital, Angers
2018 Phase 3 NCT03540810 France;
Telitacicept
Peking Union Medical College Hospital
2021 Phase 2 NCT05078710 China;